PE-Labeled Monoclonal Anti-Human CD197 / CCR7 Antibody, Mouse IgG2a (AS651) (0.03% Proclin)

製品番号/仕様
価格
Availability
数量
FABm057-01-100tests (50tests X 2)
$210.00
FABm057-01
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Monoclonal Anti-Human CD197 / CCR7 Antibody, Mouse IgG2a (AS651) is a recombinant mouse monoclonal antibody expressed in HEK293 cells, providing improved batch-to-batch consistency and long-term supply security.

Clone

AS651

Isotype

Mouse IgG2a, Kappa

Host Species

Mouse

Reactivity

Human

Immunogen

Purified Human CD197 / CCR7 Protein

Conjugate

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

Specificity

This antibody specifically recognizes human CD197 / CCR7 protein.

Application

Flow Cytometry (Evaluation of the expression of CD197 / CCR7 on Human cells).

Recommended Dilution

1:20

Isotype Control

The isotype control is sold separately; please refer to Cat. No. DNP-PM487 for product information.

Form

Liquid

Formulation

Supplied as 0.2 μm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.

Please contact us for customized product forms or formulations.

Shipping

Liquid product is shipped at blue ice.

Storage

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • Store at 2-8 °C for 12 months.
Notices

Product Specific Notices: For research use only.

バックグランド

The anti-Human CD197 (CCR7) monoclonal antibody specifically binds to cell-surface CCR7 (CD197), a seven-transmembrane G-protein-coupled receptor that interacts with chemokines CCL19 and CCL21. CCR7 mediates leukocyte homing to secondary lymphoid tissues, and its differential expression distinguishes T cell subsets. Aberrant CCR7 expression is linked to lymphoma metastasis and autoimmune disease progression, making it a key target for immunotherapy research. PE-labeled CCR7 antibody can facilitate relevant drug research and development.